SOHO 2025 | Unmet needs and treatment goals in CML: insights from a patient and physician survey

Yeah, this is a very interesting approach that we took. We interviewed patients and physicians, and we focused on first line of therapy, second line of therapy, and third line of therapy, and saw how they see the goals of therapy. That was one of the interesting elements. So, I would say that the two main takeaways from this study, well, number one is that there seems to be a little bit of a misalignment on the things that a physician focuses the most on versus the patient. So for the patient, that the disease doesn’t progress and quality of life, fewer side effects, that kind of thing, that’s mostly in the top five. Sometimes achieving a deep molecular response is included, but it’s usually like number five. Whereas for the physicians, we focus a lot more on these deep molecular responses and all of that. Certainly, we also mention side effects and quality of life, but there seems to be more of a focus on the response and kind of re-emphasizing a little bit the quality of life, the side effects, et cetera. The other important component of this was to ask the patients with the treatments that they’re receiving, how much they have an impact on their daily activities, on their work, on their relationship with others, in enjoying the things that they used to do, all these daily life activities. And for pretty much every activity that we asked about, 40 to 50 or more percent say that the treatment really impacts their ability to do those things, which puts an emphasis on the quality of life aspect where we really need to improve the focus and somehow improve the quality of life of our patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.